



(11) **EP 1 594 433 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
21.12.2016 Bulletin 2016/51

(45) Date of publication and mention
of the grant of the patent:
13.01.2016 Bulletin 2016/02

(21) Application number: **04702173.8**

(22) Date of filing: **14.01.2004**

(51) Int Cl.:
A61K 38/39 ^(2006.01) **A61K 31/00** ^(2006.01)
A61K 45/06 ^(2006.01) **A61K 38/17** ^(2006.01)
A61P 35/00 ^(2006.01) **A61K 31/513** ^(2006.01)
A61K 31/4745 ^(2006.01) **A61K 31/7048** ^(2006.01)
A61K 33/24 ^(2006.01)

(86) International application number:
PCT/US2004/000901

(87) International publication number:
WO 2004/064785 (05.08.2004 Gazette 2004/32)

(54) **CANCER THERAPY SENSITIZER**
SENSIBILISATOR FÜR KREBSTHERAPIE
SENSIBILISANT D'UNE THERAPIE DE CANCER

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: **14.01.2003 US 440009 P**

(43) Date of publication of application:
16.11.2005 Bulletin 2005/46

(60) Divisional application:
12183770.2 / 2 561 887

(73) Proprietor: **Dana-Farber Cancer Institute, Inc.**
Boston, MA 02115-5450 (US)

(72) Inventors:
• **TAI, Isabelle, T.**
Vancouver, B.C. V6Z 3A9 (CA)
• **CHEN, Lan, Bo**
Lexington, MA 02420 (US)

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
WO-A-02/089772 US-A1- 2003 082 228
US-B1- 6 406 693 US-B1- 6 475 784

- **G.K. YIU ET AL: "SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells" AMERICAN JOURNAL OF PATHOLOGY, vol. 159, no. 2, February 2001 (2001-02), pages 609-622, XP002983766**
- **I.A. CREE ET AL: "Chemosensitization of Solid Tumor Cells by Alteration of their Susceptibility to Apoptosis" CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 3, no. 4, April 2002 (2002-04), pages 641-647, XP008095641**
- **N. DHANESUAN ET AL: "Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition." BREAST CANCER RESEARCH, vol. 75, no. 1, September 2002 (2002-09), pages 73-85, XP002493062**
- **U. STEIN ET AL: "Reversal of Multidrug Resistance by Transduction of Cytokine Genes into Human Colon Carcinoma Cells" JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 88, no. 19, 2 October 1996 (1996-10-02), pages 1383-1392, XP002493063**
- **YIU G.K. ET AL: 'SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells' AM J PATHOL vol. 159, no. 2, August 2001, pages 609 - 662, XP002983766**
- **CHLENSKI A. ET AL: 'SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis' CANCER RES vol. 62, 15 December 2002, pages 7357 - 7363, XP002986916**

EP 1 594 433 B8